Showing 5521-5530 of 7029 results for "".
- FDA Approves Olumiant from Eli Lilly for Alopecia Areatahttps://practicaldermatology.com/news/fda-approves-olumiant-from-eli-lilly-for-alopecia-areata/2461231/Olumiant (baricitinib) from Eli Lilly and Company is approved to treat adult patients with severe alopecia areata. FDA action marks the first approval of a systemic treatment for alopecia areata. Olumiant is
- New Research Reveals Roughly 4 in 5 Acne Sufferers Have Missed Moments in Their Life Due to Acnehttps://practicaldermatology.com/news/new-research-reveals-roughly-4-in-5-acne-sufferers-have-missed-moments-in-their-life-due-to-acne/2461227/Ninety percent of moderate to severe acne sufferers said having acne-free skin would dramatically change the way they live their life, according to a new survey released today. The survey was conducted on behalf of Cutera, Inc., which offers AviClear, the first
- And the Winners Are...Newsweek Names America’s Top Dermatologistshttps://practicaldermatology.com/news/and-the-winners-arenewsweek-names-americas-top-dermatologists/2461226/Newsweek has released the 2022 America‘s Best Dermatologists List in partnership with Statista. The list is split into two categories: cosmetic and medical and includes 275 dermatologists (125 cosmetic and 150 medical), many of whom sit on Practical Dermatology® and sister pub
- Message from ASLMS President Dr. Paul M. Friedmanhttps://practicaldermatology.com/news/message-from-aslms-president-dr-paul-m-friedman/2461221/Dr. Paul M. Friedman, president of the American Society for Laser Medicine and Surgery (ASLMS), is calling on members to expand philanthropic programs that can help change lives with lasers. “In the coming year, I will be looking to the membership to bring their talents forwa
- FDA Accepts sBLA for Priority Review for Dupixent in PNhttps://practicaldermatology.com/news/fda-accepts-sbla-for-priority-review-for-dupixent-in-pn/2461218/FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) from Sanofi and Regeneron to treat adults with prurigo nodularis. The target action date for the FDA decision is September 30, 2022. The sBLA is supported by dat
- ASLMS Announces New Officershttps://practicaldermatology.com/news/aslms-announces-new-officers-1/2461215/Paul M. Friedman, MD is the new President of the American Society for Laser Medicine and Surgery (ASLMS). Dr. Friedman, board-certified by the American Board of Dermatology, is the director of Dermatology & Laser Surgery Center of Houston, Texas. He
- Lullage Launches in US on International Skin Pigmentation Dayhttps://practicaldermatology.com/news/lullage-launches-in-us-on-international-skin-pigmentation-day/2461213/Lullage, known as Bella Aurora in Europe and Asia, celebrates International Skin Pigmentation Day to raise awareness about the prevalence of skin pigmentation conditions and the
- Study: All Moisturizer Types Equally Effectivehttps://practicaldermatology.com/news/study-all-moisturizer-types-equally-effective/2461209/No one type of moisturizer is better than another, according to the Best Emollients for Eczema trial. This study, the first to directly compare different types of moisturizers, highlights the importance of patient education and choice when deciding which moisturizers to use for children
- Crown to Acquire Aesthetic Product Portfolio from Eclipsehttps://practicaldermatology.com/news/crown-to-acquire-aesthetic-product-portfolio-from-eclipse/2461208/Crown Laboratories will acquire the global aesthetics-focused assets of Eclipse. The acquisition expands Crown's aesthetics' product portfolio and enhances Crown's overall value proposition as a global leader in science-based aesthetic skincare solutions. "We
- CHMP Recommends Approval of Lilly and Incyte's Olumiant for Severe AAhttps://practicaldermatology.com/news/chmp-recommends-approval-of-lilly-and-incytes-olumiant-for-severe-aa/2461204/The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly and Company and Incyte’s Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA). This opinion marks the fir